Please enable Javascript
SNMMI 2022 Annual Meeting
qFME With Fluorescent Tracers Detect Lesions in Patients With Barret’s Esophagus
Emily Menendez
Gastroesophageal Cancer
|
June 13, 2024
qFME with oral administration of bevacizumab-800CW and cetuximab-800CW is feasible, and can shorten procedure time.
Utilizing [68Ga]-NeoBOMB1 for Wild Type GIST
Emily Menendez
GIST
|
June 13, 2024
NeoBOMB1 can be used in the theranostic setting for wtGIST when no effective standard of care treatment is available.
Novel Peptide Binder to Glypican-3 Shows High Specificity as a Theranostic Agent for Hepatocellular Carcinoma
Brandon Twyford
Hepatocellular Carcinoma
|
June 11, 2024
[68Ga]Ga-RYZ-GPC3 shows high specificity in detecting hepatocellular carcinoma, outperforming conventional imaging.
Study: Androgen Deprivation Therapy Does Not Affect Performance of Piflufolastat F 18-PET/CT
Kerri Fitzgerald
SNMMI
|
April 23, 2023
Piflufolastat F 18 is a radiopharmaceutical that targets the prostate-specific membrane antigen during imaging.
Cross-Training Healthcare Clinicians and Technicians Can Help Alleviate Staffing Shortages
Kerri Fitzgerald
SNMMI
|
August 9, 2022
This model assigns workers to additional or alternate roles that match existing skills and providing proper re-training.
68Ga-PSMA PET/CT Improves Prostate Cancer Diagnosis Compared With Multiparametric MRI
Kerri Fitzgerald
SNMMI
|
August 9, 2022
Researchers retrospectively analyzed patients who had received both 68Ga-PSMA PET/CT and mpMRI testing.
New PET Imaging Agent Can Predict Response to CAR T-Cell Therapy
Kerri Fitzgerald
SNMMI
|
September 21, 2023
The approach may help inform clinical decision-making early in treatment.
PSMA PET Research Supports Updates to Guidelines for Prostate Cancer Treatment
Kerri Fitzgerald
SNMMI
|
August 9, 2022
Updates may be needed to guidelines for salvage radiation treatments in patients with local recurrence of prostate ...
Be Aware of Threats to Data Integrity in Medical Imaging
Kerri Fitzgerald
SNMMI
|
August 9, 2022
Developers and users must be aware of the potential for data attacks and manipulation when considering AI models for ...
Phase 2 Study Supports Radionuclide Alpha Therapy in Patients With Advanced Neuroendocrine Tumors
Kerri Fitzgerald
SNMMI
|
August 24, 2023
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Study: New AI Scan Strategy Can Cut Radiation Exposure in Half
Kerri Fitzgerald
SNMMI
|
June 30, 2023
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
Study Supports Combination of PSMA and GRP-R-PET for Prostate Cancer Staging
Kerri Fitzgerald
SNMMI
|
August 9, 2022
Researchers conducted a prospective phase 2 imaging study to compare PSMA and GRP-R-targeted imaging during initial ...
Guided Imagery Can Reduce Stress for Patients and Providers in Nuclear Medicine and Radiology Departments
Kerri Fitzgerald
SNMMI
|
August 9, 2022
Guided imagery can enhance coping, reduce anxiety, and decrease heart rate, respirations, and blood pressure.
Quantitative Parametric Imaging Improves Prostate Cancer Lesion Detection
Kerri Fitzgerald
SNMMI
|
August 9, 2022
A study explore values of parametric Ki imaging in total-body 68Ga-PSMA-11 PET/CT in patients with prostate cancer.
SNMMI Task Force Outlines Key Opportunities, Challenges, and Considerations in Artificial Intelligence
Kerri Fitzgerald
SNMMI
|
April 11, 2023
The framework emphasizes the importance of establishing trust among stakeholders.
PET/CT Effective in Post-COVID Evaluation and Monitoring
Kerri Fitzgerald
SNMMI
|
April 23, 2023
The study is the first to show that lingering COVID-19 symptoms can be attributed to ongoing lung inflammation.
Advertisement
Advertisement
Advertisement
Advertisement